

113  
concluded  
antigen (PSMA), purified prostate specific membrane antigen (PSMA), a peptide having the amino acid sequence LLHETDSAV (SEQ. ID. NO. 1), a peptide having the amino acid sequence ALFDIESKV (SEQ. ID. NO. 2), a peptide having the amino acid sequence XL(or M)XXXXXXV(or L) (SEQ. ID. NO. 3), where X represents any amino acid, purified prostate specific antigen (PSA), or a purified prostate mucin antigen recognized by monoclonal antibody PD41.

30. (new) The composition according to claim 28, in which the dendritic cells are extended life span dendritic cells.

---

#### REMARKS

The present application was filed, claiming priority benefits under 35 U.S.C. § 120, as a continuation of PCT/US96/12389, filed July 29, 1996, which is continuation-in-part of U.S. Patent Application Serial No. 08/509,254, filed July 31, 1995 (*see* the executed Declaration and Powder of Attorney in connection with the present application, which was filed with the United States Patent and Trademark Office on April 7, 1998 and the unexecuted Declaration and Powder of Attorney in connection with the present application, which was filed with the United States Patent and Trademark Office on January 30, 1998). In order to properly recite the lineage of the applications, the first sentence of the present specification has been amended to specifically recite that it is a continuation of PCT/US96/12389, filed July 29, 1996, now pending, which is a continuation-in-part of U.S. Patent Application Serial No. 08/509,254, filed July 31, 1995, now U.S. Patent No. 5,788,963.

Upon entry of the present Preliminary Amendment, claims 1-30 are currently pending in this application. By this Preliminary Amendment, Applicants have amended claims 23-24. Applicants have also added new claims 27-30.

Support for amended claims 23-24, which are directed to isolated human dendritic cells, can be found, *inter alia*, at page 5, second full paragraph of the present specification wherein it is disclosed that the present invention provides compositions comprising isolated human dendritic cells as well as cryopreserved isolated human dendritic cells (emphasis added); and at page 22, Section 6.1.3. and pages 24-25, Section 6.2. of the present specification wherein isolation of dendritic cells from peripheral blood without cryopreservation is disclosed.

Support for amended claims 23-24 and new claims 27-30, which are directed to isolated human dendritic cells which have been exposed to a prostate tissue antigen or to any of a number of recited specific peptides, can be found, *inter alia*, at pages 13-17, Section 5.2. of the present specification entitled "Prostate Specific Antigens for Presentation by Dendritic Cells," wherein it is disclosed that isolated dendritic cells are exposed to prostate specific membrane antigen (PSMA), or an antigenic peptide having the amino acid sequence LLHETDSAV (SEQ. ID. NO. 1) which corresponds to amino acid residues 4-12 of PSMA; or an antigenic peptide selected from the peptides listed in Table 1A which have amino acid sequences corresponding to fragments of PSMA, or prostate specific antigen (PSA); or an antigenic peptide selected from the peptides listed in Table 1B which have amino acid sequences corresponding to fragments of PSA, or a prostate mucin antigen, recognized by monoclonal antibody PD41.

Therefore, the amended and new claims are supported by the specification and claims as originally filed and no new matter is added by the above amendments and additions.


Submitted herewith is an IDS with revised PTO Form 1449 listing references AA-DM. References AA-DK can be found in the file of U.S. Patent Application Serial No. 08/509,254 and references DL-DM are submitted herewith the IDS. It is requested that all references are made of record in the file.

**CONCLUSION**

In light of the above amendments and remarks, it is respectfully submitted that the amended claims are in form for issuance and an early allowance is earnestly requested.

Respectfully submitted,

Date December 1, 1998

  
Geraldine F. Baldwin 31,232  
(Reg. No.)

**PENNIE & EDMONDS LLP**  
1155 Avenue of the Americas  
New York, New York 10036-2711  
(212) 790-9090